James L. Freddo

1.5k total citations
27 papers, 1.2k citations indexed

About

James L. Freddo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, James L. Freddo has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in James L. Freddo's work include Ovarian cancer diagnosis and treatment (6 papers), Hepatitis C virus research (6 papers) and Intraperitoneal and Appendiceal Malignancies (4 papers). James L. Freddo is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Hepatitis C virus research (6 papers) and Intraperitoneal and Appendiceal Malignancies (4 papers). James L. Freddo collaborates with scholars based in United States, Spain and Netherlands. James L. Freddo's co-authors include George Wilding, Steven D. Reich, Glenn Liu, Heidi Steinfeldt, John W. Park, Merrill S. Kies, Yazdi K. Pithavala, Roy S. Herbst, Hope S. Rugo and Sinil Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

James L. Freddo

27 papers receiving 1.2k citations

Peers

James L. Freddo
Jane Robertson United Kingdom
Henrik Roed Denmark
He Huang China
Eduard Vrdoljak Croatia
David Gallagher Ireland
Irshad Soomro United Kingdom
Heinz Josef Lenz United States
Jesús García-Donás Spain
Marta Gil-Martín Spain
Alessandra Ravaioli Italy
Jane Robertson United Kingdom
James L. Freddo
Citations per year, relative to James L. Freddo James L. Freddo (= 1×) peers Jane Robertson

Countries citing papers authored by James L. Freddo

Since Specialization
Citations

This map shows the geographic impact of James L. Freddo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James L. Freddo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James L. Freddo more than expected).

Fields of papers citing papers by James L. Freddo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James L. Freddo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James L. Freddo. The network helps show where James L. Freddo may publish in the future.

Co-authorship network of co-authors of James L. Freddo

This figure shows the co-authorship network connecting the top 25 collaborators of James L. Freddo. A scholar is included among the top collaborators of James L. Freddo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James L. Freddo. James L. Freddo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Riedel, Richard F., Sant P. Chawla, Mihaela Druta, et al.. (2023). ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). TPS11583–TPS11583. 1 indexed citations
2.
D’Angelo, Sandra P., Steven I. Robinson, Bonne J. Adams, et al.. (2021). ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.. Journal of Clinical Oncology. 39(15_suppl). TPS11581–TPS11581. 5 indexed citations
3.
Robert, Francisco, Ecaterina E. Dumbrava, Yan Xing, et al.. (2021). Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.. Journal of Clinical Oncology. 39(15_suppl). 2511–2511. 13 indexed citations
4.
5.
Rahimy, Mohamad H., et al.. (2014). Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. Clinical Therapeutics. 36(12). 2047–2063.e3. 7 indexed citations
6.
Braud, Filippo de, Lorenzo Pilla, Monica Niger, et al.. (2014). Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations. Annals of Oncology. 25. iv148–iv148. 7 indexed citations
7.
Bergmann, Jean‐François, Joep de Bruijne, Robert J. de Knegt, et al.. (2011). Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Alimentary Pharmacology & Therapeutics. 34(4). 443–453. 43 indexed citations
8.
Boonstra, André, Bisheng Liu, Zwier M. A. Groothuismink, et al.. (2011). Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7. Antiviral Therapy. 17(4). 657–667. 25 indexed citations
9.
Läwitz, E., Vinod K. Rustgi, Tarek Hassanein, et al.. (2010). 2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS. Journal of Hepatology. 52. S467–S467. 34 indexed citations
10.
Fletcher, Simon P., Lisa Bauman, Marina G. Sergeeva, et al.. (2009). 944 PK/PD ASSESSMENT OF A PHASE 1 HEALTHY VOLUNTEER STUDY WITH ANA773, AN ORAL PRODRUG OF A TLR7 AGONIST FOR THE TREATMENT OF HCV. Journal of Hepatology. 50. S343–S343. 1 indexed citations
11.
Rixe, Olivier, Ronald M. Bukowski, M. Dror Michaelson, et al.. (2007). Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet Oncology. 8(11). 975–984. 356 indexed citations
12.
Rugo, Hope S., Roy S. Herbst, Glenn Liu, et al.. (2005). Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. Journal of Clinical Oncology. 23(24). 5474–5483. 410 indexed citations
13.
Plaxe, Steven C., R D Christen, John O’Quigley, et al.. (1998). Phase I and pharmacokinetic study of intraperitoneal topotecan. Investigational New Drugs. 16(2). 147–153. 23 indexed citations
14.
Spirtos, Nick M., Gary M. Gross, James L. Freddo, & Samuel C. Ballon. (1996). Cytoreductive Surgery in Advanced Epithelial Cancer of the Ovary. Obstetrical & Gynecological Survey. 51(1). 23–25. 1 indexed citations
15.
Spirtos, Nick M., Gary M. Gross, James L. Freddo, & Samuel C. Ballon. (1995). Cytoreductive Surgery in Advanced Epithelial Cancer of the Ovary: The Impact of Aortic and Pelvic Lymphadenectomy. Gynecologic Oncology. 56(3). 345–352. 69 indexed citations
16.
Plaxe, Steven C., James L. Freddo, Sinil Kim, et al.. (1994). Phase I Trial of Cisplatin in Combination with Glutathione. Gynecologic Oncology. 55(1). 82–86. 18 indexed citations
17.
McClay, Edward F., Steven C. Plaxe, S. S. C. YEN, et al.. (1993). Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.. Journal of Clinical Oncology. 11(12). 2417–2426. 31 indexed citations
18.
Plaxe, Steven C., Patricia S. Braly, James L. Freddo, et al.. (1993). Phase I and Pharmacokinetic Study of Intraperitoneal Ormaplatin. Gynecologic Oncology. 51(1). 72–77. 3 indexed citations
19.
Rogers, Leland, Mahesh A. Varia, Jan Halle, et al.. (1993). 32P Following Negative Second-Look Laparotomy for Epithelial Ovarian Cancer. Gynecologic Oncology. 50(2). 141–146. 9 indexed citations
20.
Rogers, Leland, Mahesh A. Varia, Jan Halle, et al.. (1990). 32P following second-look laparotomy for epithelial ovarian cancer. International Journal of Radiation Oncology*Biology*Physics. 19. 167–168. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jane Robertson Breakdown of academic impact, for papers by Henrik Roed Breakdown of academic impact, for papers by He Huang Breakdown of academic impact, for papers by Eduard Vrdoljak Breakdown of academic impact, for papers by David Gallagher Breakdown of academic impact, for papers by Irshad Soomro Breakdown of academic impact, for papers by Heinz Josef Lenz Breakdown of academic impact, for papers by Jesús García-Donás Breakdown of academic impact, for papers by Marta Gil-Martín Breakdown of academic impact, for papers by Alessandra Ravaioli
Rankless by CCL
2026